

introduced. Theoretically, as the name suggests, it is a substance specific to the membrane of prostate cells and prostate cancer. However, several studies have shown that it is also a marker of neoangiogenesis, leading to its uptake in various other neoplasms and benign diseases. **Objectives:** This study aims to evaluate the utility of radiolabeled PSMA in detecting desmoid tumors, comparing it to 18F-fluorodeoxyglucose (FDG). **Materials and Methods:** Three participants with a confirmed diagnosis of desmoid tumor underwent PET/CT examinations with 18F-PSMA and 18F-FDG, with a maximum interval of 3 days between examinations. Images were visually compared lesion by lesion and the maximum standardized uptake value (SUV) was calculated for each lesion and each radiopharmaceutical. **Results:** All lesions presented uptake of both 68Ga-PSMA and 18F-FDG. In the first patient, 3 lesions were identified: a mass adjacent to the pancreas measuring 5.4 cm (FDG: SUV = 2.0) (PSMA: SUV = 8.2), a mass in the right iliac fossa measuring 7.7 cm (FDG: SUV = 3.8) (PSMA: SUV = 5.7), and another involving the duodenojejunal transition measuring 4.1 cm (FDG: SUV = 1.9) (PSMA: SUV = 3.7). In the second patient, a mass was identified adjacent to the head and uncinate process of the pancreas measuring 9.2 cm (FDG: SUV = 9.8) (PSMA: SUV = 6.1). In the third patient, an irregular retroperitoneal mass was identified at the level of the aortic bifurcation (FDG: SUV = 2.3) (PSMA: SUV = 2.4). **Conclusion:** Desmoid tumors can demonstrate uptake of both 68Ga-PSMA and 18F-FDG. The intensity of tracer uptake in the lesions is variable, with some showing greater uptake of FDG, others of PSMA, suggesting a potential complementary role for these radiotracers in desmoid tumors.

Keywords: Cancer, Desmoid tumor, PET/CT, PSMA-18F, PSMA-68Ga.

<https://doi.org/10.1016/j.htct.2024.04.080>

INFLUENCE OF A CONVENTIONAL CHELATOR-MODIFIED ANTI-INTEGRIN PEPTIDE ON PROLIFERATION AND MIGRATION OF HEAD AND NECK CANCER CELLS

Juliana Carron ^a, Daniele Daiane Affonso ^a,
Suelen Aparecida Ribeiro Souza ^a,
Ana Maria Castro Ferreira ^a,
João Ernesto Carvalho ^b,
Ana Lucia Tasca Gois Ruiz ^b,
Gabriella Fraiji Melo ^c, Flávio Lopes Alves ^c,
Leonardo Lima Fuscaldi ^c, Luciana Malavolta ^c,
Carmen Silvia Passos Lima ^d

^a Laboratório de Genética do Câncer, Faculdade de Ciências Médicas (FCM), Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil

^b Faculdade de Ciências Farmacêuticas (FCF), Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil

^c Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil

^d Divisão de Oncologia Clínica, Departamento de Anestesiologia, Oncologia e Radiologia, Faculdade

de Ciências Médicas (FCM), Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil

Introduction/Justification: Head and neck squamous cell carcinoma (HNSCC) represents a serious health problem worldwide. Approximately 75% of patients with HNSCC have locally advanced disease at diagnosis, and the therapy for those cases involves chemoradiation or induction chemotherapy, in which cisplatin is included despite of its substantial side effects. FAPESP-founded “Cancer Innovation Center with Emphasis on Metals and Theranostics” (CancerThera) is dedicated to the development of new metallopharmaceuticals and radiopharmaceuticals for tumor diagnosis and treatment. Among these developments, an anti-integrin peptide modified by a conventional spacer (C6) and chelator (DOTA) was evaluated as a potential treatment of HNSCC. Overexpressed in HNC, integrins are transmembrane proteins that play essential roles in cell proliferation and migration. Therefore, integrin inhibition may be a potential targeted therapy for HNC patients. **Objectives:** The study aimed to evaluate the effects of the DOTA-C6-anti-integrin peptide on HNSCC cell lines proliferation and migration, as an initial step for HNSCC theranostic development. **Materials and Methods:** The anti-proliferative activity of the DOTA-C6-anti-integrin peptide (0.01nM - 100μM) was assessed against FaDu and SCC-25 cells by considering the cell amounts at baseline and 48h after exposure (two untreated control groups). All cells were fixed with 50% trichloroacetic acid and stained with sulforhodamine B. Spectrophotometric absorbance was performed at 540nm in a microplate reader. Cell migration was assessed in FaDu cells and FaDu cells treated with the DOTA-C6-anti-integrin peptide (1, 10, and 100μM) using the wound-healing assay. Wound cells were photographed immediately (0h) and after 16h, 24h, and 40h. Images were analyzed by the ImageJ software (National Institutes of Health). For statistical analysis, samples did assume normal distribution in Shapiro-Wilk's test, thus we used t test to compare the groups using SPSS 21 software (SPSS Incorporation). **Results:** At the tested concentration range, the DOTA-C6-anti-integrin peptide did not affect proliferation of FaDu or SCC-25 cells. In FaDu cells, the DOTA-C6-anti-integrin peptide significantly ($p < 0.05$) inhibited migration in comparison to untreated cells, independent on sample concentration (1, 10, and 100μM) or time exposure (16, 24, or 40 h). **Conclusion:** Despite the lack of anti-proliferative effect, the DOTA-C6-anti-integrin peptide inhibited migration in FaDu cells. As cell migration is an important process in HNSCC progression, our data present preliminary evidence that the DOTA-C6-anti-integrin may be used in development of theranostic agents for HNSCC. **Acknowledgements:** The study was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNP #429463/2018-9), Fundação de Apoio ao Ensino e à Pesquisa do Estado de São Paulo (FAPESP #2023/09738-4, FAPESP #2023/012810-9, Cancer Theranostics Innovation Center, (CancerThera), CEPID FAPESP #2021/10265-8), and International Atomic Energy Agency (IAEA) technical cooperation projects for development of Latin American Countries (IAEA/TCLAC: EX-BRA6033-2401375).

Keywords: Cell migration, Head and neck cancer, Theranostic.

<https://doi.org/10.1016/j.htct.2024.04.081>